Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir

Article Abstract:

Treating HIV infection with two protease inhibitors simultaneously may be beneficial, according to a study of 33 patients. However, four patients who did not respond to this treatment were found to have protease-resistant virus even though none had protease-resistant virus when they began treatment.

Author: Eron, Joseph J., Haubrich, Richard, Lang, William, Pagano, Grace, Millard, Judith, Wolfram, Josie, Snowden, Wendy, Pedneault, Louise, Tisdale, Margaret
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Comparison of two indinavir/ritonavir in the treatment of HIV-infected individuals

Article Abstract:

The two-ritonavir/indinavir regimens in the treatment of HIV-infected individuals are compared. Both regimens exhibited similar tolerability and response rates and high toxicity with a low response suggests that the optimum IDV/RTV combination would include an RTV dose<400mg and an IDV dose <800mg in the population.

Author: Kuritzkes, Daniel R., Eron, Joseph J., Saah, Alfred J., Acosta, Edward P., Walawander Ann, Ferguson, Elaine, Hulin Wu, Song Yu, Pettinelli Carla, Neath, Denise
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
Care and treatment, Ritonavir, Indinavir

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151

Article Abstract:

Two fat-soluble formulations of the HIV protease inhibitor SC-52151 appear to be well-tolerated. This drug is not soluble in water so two other formulations have been developed: an ethanol-based elixir and a self-emulsifying drug delivery system (SEDDS). Forty-nine HIV-infected patients were randomly assigned to take 2,250 milligrams of either formulation two or three times a day. The SEDDS formulation resulted in higher drug concentrations as did twice daily administration. There were few serious side effects but the drug did not substantially affect HIV RNA levels.

Author: Richman, Douglas D., Fischl, Margaret A., Flexner, Charles, Para, Michael F., Haubrich, Richard, Holden-Wiltse, Jeanne, Meehan, Patricia M., Karim, Aziz, Yeramian, Patrick
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1997
Antiviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, HIV infection, Drug therapy, HIV infections, Protease inhibitors, Dosage and administration
Similar abstracts:
  • Abstracts: Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses
  • Abstracts: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice
  • Abstracts: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
  • Abstracts: Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1-infected patients
  • Abstracts: Same-sex behavior and high rates of HIV among men attending sexually transmitted infection clinics in Pune, India (1993-2002)
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2023 Advameg, Inc.